Britain’s Cancer Research Technology Ltd. says the dire financing situation facing European biotechs has forced it to become a bridge builder between research-based Big Pharma and academia, an intermediary role that it expects to expand on as the search for new oncology drugs intensifies.
Lack of funding in Europe for early-stage biotech companies has forced CRT, the technology transfer arm of the charity